ResearchMoz

Humulin (Type 2 Diabetes) - Analysis and Forecasts to 2020

GlobalData
Published Date » 2012-01-31
No. Of Pages » 44


GlobalDatas pharmaceuticals report, Humulin (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Humulin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Humulin including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Humulin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Humulin in each of the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17
5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19
6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Humulin 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Different Variants of Humulin 25
7.4 Clinical Studies 25
7.4.1 Safety & Efficacy Study in Humalog & Humulin R 25
7.4.2 Safety & Efficacy Study in Lantus & NPH Insulin 26
7.5 Approval History of Humulin 27
7.6 Factors Affecting Sales 27
7.6.1 First in Class 27
7.6.2 Growing Insulin Market 28
7.6.3 Advantage of Insulin Analogs over Humulin 28
7.6.4 Family of Humulin Products 28
7.6.5 Co-Branding Deal with Wal-Mart 28
7.6.6 Availability as OTC 28
7.6.7 No Competition from Biosimilars 28
7.7 Drug Evaluation 29
7.7.1 Drug Risk Benefit Score 29
7.7.2 Intensity of Competition 30
7.8 Sales Estimates 30
7.8.1 Dosing 30
7.8.2 Market Penetration 30
7.8.3 Annual Cost of Therapy 31
7.8.4 Sales Projections of Humulin 32

8 Diabetes Market: Appendix 41
8.1 Market Definitions 41
8.2 List of Abberiviations 41
8.3 Research Methodology 41
8.3.1 Coverage 42
8.3.2 Secondary Research 42
8.3.3 Forecasting 42
8.3.4 Number of patients approved to take the drug 42
8.3.5 Net Penetration of Drug 43
8.3.6 Net Annual Dosing 43
8.3.7 Annual Cost of Therapy 43
8.4 Drug Sales Estimates Model 43
8.5 Contact Us 43
8.6 Disclaimer 44
8.7 Sources 44

List of Tables


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Type 2 Diabetes Mellitus Adults 26
Table 10: Efficacy and Insulin Dosage in Type 2 Diabetes Mellitus 27
Table 11: Approval of Humulin in the US 27
Table 12: Drug Risk Benefit Score of Humulin R 29
Table 13: Drug Risk Benefit Score of Humulin N 29
Table 14: Humulin R, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 15: Humulin N, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 16: Humulin PreMix, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 17: Humulin Franchise, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 18: Humulin, Type 2 Diabetes, Global, Sales Estimates ($m), 20022020 32
Table 19: Humulin, Type 2 Diabetes, The US, Sales Estimates ($m), 20022020 33
Table 20: Humulin, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022020 34
Table 21: Humulin, Type 2 Diabetes, France, Sales Estimates ($m), 20022020 35
Table 22: Humulin, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022020 36
Table 23: Humulin, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022020 37
Table 24: Humulin, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022020 38
Table 25: Humulin, Type 2 Diabetes, Japan, Sales Estimates ($m), 20022020 39

List of Figures


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylureas 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Branded Market Share By Class (%), 2010 24
Figure 12: Humulin, Type 2 Diabetes, Global, Sales Estimates ($m), 2002-2020 32
Figure 13: Humulin, Type 2 Diabetes, The US, Sales Estimates ($m), 20022020 33
Figure 14: Humulin, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022020 34
Figure 15: Humulin, Type 2 Diabetes, France, Sales Estimates ($m), 20022020 35
Figure 16: Humulin, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022020 36
Figure 17: Humulin, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022020 37
Figure 18: Humulin, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022020 38
Figure 19: Humulin, Type 2 Diabetes, Japan, Sales Estimates ($m), 2002-2020 39
Figure 20: Humulin, Diabetes, Global, Sales Distribution by Country (%), 2020 40
Figure 21: Patients Approved for the Drug 43

Upcoming Reports:

Greece: garlic market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the garlic market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the garlic market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main market...
Mouth Ulcers Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Mouth ulcer, also termed as mucosal ulcer, is a common oral disorder that occurs on the mucous membrane of an oral cavity. A sore or a lesion develops in the mouth, usually red and swollen on the inside of cheeks or lips. Mouth ulcers are common, particularly in women and young adults. It often cause pain and discomfort while eating, drinking and brushing one’s teeth. The two most common causes of mouth ulcers include aphthous stomatitis (canker sores) and local trauma. Other causes include gingivostomatitis, herpes simplex virus, leukoplakia and oral lichen planus. ...
Poland: footwear market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the footwear market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the footwear market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

Order cancellations not a sign of market slump: Airbus
Jul 31, 2014  
Leading aircraft manufacturer Airbus on Wednesday said that the recent wave of order cancellations for its commercial jetliners do not mean that the market has declined. The market is still strong and single-aisle jets deals are likely to return later. A total of 225 Airbus cancellations were reported since the beginning of this year. Of these, Dubai’s Emirates Airlines alone...
Leading Australian Universities Want to Hike Fees, Enroll Fewer Students
Jul 31, 2014  
Australia’s prestigious group of top eight universities, also known as the Group of Eight (Go8), has indicated plans of increasing tuition fees while reducing the number of students they enroll, a reform-backer has predicted. These decisions could be made if the universities are deregulated .  Arguing for this decision, the chairman of Go8, and vice chancellor of the ANU, Ian...
Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...
Second Treaty Between Zealand And Boehringer Ingelheim
Jul 30, 2014  
Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma.  Both these companies are aiming...